Importantly, melatonin counteracted the stimulatory effect of doxorubicin over the expression of NME1 (a supressor or metastasis in breast carcinoma) [28]; MUC1 (a p53 supressor) [29]; SNAI2 (involved in invasion and EMT) [30]; BIRC5 (involved in doxorubicin resistance) [31]; and TWIST1 (elevated in invasive breast cancer and involved in EMT [32,33] (Figure 3A). This evidence concerns the gene NME1 and invasive breast carcinoma.